## Ralph R Weichselbaum

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5097615/publications.pdf

Version: 2024-02-01

190 papers

22,163 citations

66 h-index 143 g-index

194 all docs

194 docs citations

times ranked

194

27933 citing authors

#	Article	IF	Citations
1	<i>Lactobacillus rhamnosus GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade. Gut, 2022, 71, 521-533.</i>	6.1	108
2	A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. Journal of Thoracic Oncology, 2022, 17, 130-140.	0.5	49
3	Dimethylaminomicheliolide Sensitizes Cancer Cells to Radiotherapy for Synergistic Combination with Immune Checkpoint Blockade. Advanced Therapeutics, 2022, 5, 2100160.	1.6	O
4	Radiotherapy and immunotherapy: open questions and future strategies. Trends in Cancer, 2022, 8, 9-20.	3.8	49
5	Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels. Annals of Surgical Oncology. 2022. 29. 4583-4592.	0.7	4
6	Immunotherapy for the Neoadjuvant Management of Resectable Intrathoracic Cancers. JAMA Oncology, 2022, 8, 333.	3.4	2
7	Synergistic checkpoint-blockade and radiotherapy–radiodynamic therapy via an immunomodulatory nanoscale metal–organic framework. Nature Biomedical Engineering, 2022, 6, 144-156.	11.6	47
8	p52 signaling promotes cellular senescence. Cell and Bioscience, 2022, 12, 43.	2.1	4
9	Loss of MEN1 function impairs DNA repair capability of pancreatic neuroendocrine tumors. Endocrine-Related Cancer, 2022, 29, 225-239.	1.6	3
10	Combined radio-immunotherapy: An opportunity to increase the therapeutic ratio of oligometastasis-directed radiotherapy. Neoplasia, 2022, 27, 100782.	2.3	1
11	The oligometastatic spectrum in the era of improved detection and modern systemic therapy. Nature Reviews Clinical Oncology, 2022, 19, 585-599.	12.5	39
12	(Oligo)metastasis as a Spectrum of Disease. Cancer Research, 2021, 81, 2577-2583.	0.4	22
13	Drug–Radiotherapy Combination Trial Developments—Response. Clinical Cancer Research, 2021, 27, 356-356.	3.2	O
14	Suppression of local type I interferon by gut microbiota–derived butyrate impairs antitumor effects of ionizing radiation. Journal of Experimental Medicine, 2021, 218, .	4.2	49
15	Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. Science Translational Medicine, 2021, 13, .	5.8	35
16	CDK1 is up-regulated by temozolomide in an NF-κB dependent manner in glioblastoma. Scientific Reports, 2021, 11, 5665.	1.6	14
17	The AIM2 and NLRP3 inflammasomes trigger IL-1–mediated antitumor effects during radiation. Science Immunology, 2021, 6, .	5 <b>.</b> 6	33
18	Small Animal IMRT Using 3D-Printed Compensators. International Journal of Radiation Oncology Biology Physics, 2021, 110, 551-565.	0.4	7

#	Article	IF	Citations
19	The relationship between expression of PD-L1 and HIF- $\hat{\Pi}$ ± in glioma cells under hypoxia. Journal of Hematology and Oncology, 2021, 14, 92.	6.9	80
20	Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 5510-5518.	3.2	23
21	Radiotherapy and Immunotherapy Combinations in the Treatment of Patients with Metastatic Disease: Current Status and Future Focus. Clinical Cancer Research, 2021, 27, 5188-5194.	3.2	9
22	The Spectrum of Metastasis: An Opportunity for Cure?. Seminars in Radiation Oncology, 2021, 31, 174-179.	1.0	7
23	Prospective Clinical Investigation of the Efficacy of Combination Radiation Therapy With Immune Checkpoint Inhibition. International Journal of Radiation Oncology Biology Physics, 2021, 111, 1165-1175.	0.4	8
24	Treatment of Cancer with Radio-Immunotherapy: What We Currently Know and What the Future May Hold. International Journal of Molecular Sciences, 2021, 22, 9573.	1.8	10
25	Immunoradiotherapy goes club(bing). Nature Cancer, 2021, 2, 871-872.	5.7	2
26	All-trans retinoic acid overcomes solid tumor radioresistance by inducing inflammatory macrophages. Science Immunology, 2021, 6, .	5.6	24
27	CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Scientific Reports, 2021, 11, 20059.	1.6	53
28	Reprogramming of Neutrophils as Non-canonical Antigen Presenting Cells by Radiotherapyâ€"Radiodynamic Therapy to Facilitate Immune-Mediated Tumor Regression. ACS Nano, 2021, 15, 17515-17527.	7.3	22
29	Western Diet Promotes Intestinal Colonization by Collagenolytic Microbes and Promotes Tumor Formation After Colorectal Surgery. Gastroenterology, 2020, 158, 958-970.e2.	0.6	53
30	Nanoscale metal-organic frameworks for x-ray activated in situ cancer vaccination. Science Advances, 2020, 6, .	4.7	40
31	p50 mono-ubiquitination and interaction with BARD1 regulates cell cycle progression and maintains genome stability. Nature Communications, 2020, 11, 5007.	5.8	8
32	Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clinical Cancer Research, 2020, 26, 6437-6444.	3.2	43
33	RIG-l–Like Receptor LGP2 Is Required for Tumor Control by Radiotherapy. Cancer Research, 2020, 80, 5633-5641.	0.4	27
34	The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes. Frontiers in Immunology, 2020, 11, 580335.	2.2	6
35	Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling. Journal of Experimental Medicine, 2020, 217, .	4.2	172
36	4-Hydroxyacetophenone modulates the actomyosin cytoskeleton to reduce metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 22423-22429.	3.3	24

#	Article	IF	CITATIONS
37	Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells. Nature Communications, 2020, 11, 4591.	5.8	81
38	Oligometastasis: Past, Present, Future. International Journal of Radiation Oncology Biology Physics, 2020, 108, 530-538.	0.4	27
39	Cytoreduction and the Optimization Of Immune Checkpoint Inhibition with Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2020, 108, 17-26.	0.4	18
40	Lack of supporting data make the risks of a clinical trial of radiation therapy as a treatment for COVID-19 pneumonia unacceptable. Radiotherapy and Oncology, 2020, 147, 217-220.	0.3	49
41	Fecal microbiota transplant rescues mice from human pathogen mediated sepsis by restoring systemic immunity. Nature Communications, 2020, 11, 2354.	5 <b>.</b> 8	75
42	Methodological Development of Combination Drug and Radiotherapy in Basic and Clinical Research. Clinical Cancer Research, 2020, 26, 4723-4736.	3.2	23
43	Response Letter: Radiation therapy for COVID-19 pneumopathy. Radiotherapy and Oncology, 2020, 149, 238-239.	0.3	3
44	A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 107, 487-498.	0.4	29
45	DDX39B interacts with the pattern recognition receptor pathway to inhibit NF-l̂ºB and sensitize to alkylating chemotherapy. BMC Biology, 2020, 18, 32.	1.7	16
46	Cooperation of genes in HPV16 <i>E6/E7</i> dependent cervicovaginal carcinogenesis trackable by endoscopy and independent of exogenous estrogens or carcinogens. Carcinogenesis, 2020, 41, 1605-1615.	1.3	8
47	Radiotherapy and Immunotherapy for Cancer: From "Systemic―to "Multisite― Clinical Cancer Research, 2020, 26, 2777-2782.	3.2	103
48	STING (or SRC) Like an ICB: Priming the Immune Response in Pancreatic Cancer. Cancer Research, 2019, 79, 3815-3817.	0.4	5
49	Integration of radiotherapy and immunotherapy for treatment of oligometastases. Lancet Oncology, The, 2019, 20, e434-e442.	5.1	98
50	Tumor-reprogrammed resident T cells resist radiation to control tumors. Nature Communications, 2019, 10, 3959.	5.8	151
51	Ultrathin Metal-Organic-Layer Mediated Radiotherapy-Radiodynamic Therapy. Matter, 2019, 1, 1331-1353.	5.0	78
52	Integrated molecular and clinical staging defines the spectrum of metastatic cancer. Nature Reviews Clinical Oncology, 2019, 16, 581-588.	12.5	52
53	Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors. Nature Communications, 2019, 10, 1899.	5.8	195
54	Systemic miRNA delivery by nontoxic nanoscale coordination polymers limits epithelial-to-mesenchymal transition and suppresses liver metastases of colorectal cancer. Biomaterials, 2019, 210, 94-104.	5.7	27

#	Article	IF	CITATIONS
55	Temozolomide Treatment Induces IncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma. Cancer Research, 2019, 79, 2536-2548.	0.4	71
56	Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells. Nature, 2019, 566, 270-274.	13.7	681
57	Molecular Classification of Lymph Node Metastases Subtypes Predict for Survival in Head and Neck Cancer. Clinical Cancer Research, 2019, 25, 1795-1808.	3.2	24
58	STING Promotes Homeostasis via Regulation of Cell Proliferation and Chromosomal Stability. Cancer Research, 2019, 79, 1465-1479.	0.4	64
59	Oxygen-Guided Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 103, 977-984.	0.4	59
60	A Critical Role of the IL-1β–IL-1R Signaling Pathway in Skin Inflammation and Psoriasis Pathogenesis. Journal of Investigative Dermatology, 2019, 139, 146-156.	0.3	152
61	DNA Methylation Controls Metastasis-Suppressive 14q32-Encoded miRNAs. Cancer Research, 2019, 79, 650-662.	0.4	52
62	Ultrathin metal-organic layer-mediated radiotherapy-radiodynamic therapy enhances immunotherapy of metastatic cancers. Matter, 2019, 1, 1331-1353.	5.0	20
63	JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non–small Cell Lung Cancers. Molecular Cancer Therapeutics, 2018, 17, 732-739.	1.9	18
64	ROS modifiers and NOX4 affect the expression of the survivin-associated radio-adaptive response. Free Radical Biology and Medicine, 2018, 123, 39-52.	1.3	19
65	Retuning the Radio in Radiobiology. Journal of the National Cancer Institute, 2018, 110, 325-326.	3.0	0
66	Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nature Communications, 2018, 9, 1793.	5.8	188
67	Low-dose X-ray radiotherapy–radiodynamic therapy via nanoscale metal–organic frameworks enhances checkpoint blockade immunotherapy. Nature Biomedical Engineering, 2018, 2, 600-610.	11.6	438
68	HMG-CoA Reductase Inhibition Delays DNA Repair and Promotes Senescence After Tumor Irradiation. Molecular Cancer Therapeutics, 2018, 17, 407-418.	1.9	36
69	Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2018, 36, 1611-1618.	0.8	448
70	The 46th David A. Karnofsky Memorial Award Lecture: Oligometastasisâ€"From Conception to Treatment. Journal of Clinical Oncology, 2018, 36, 3240-3250.	0.8	49
71	Nanoscale Metal–Organic Frameworks for Therapeutic, Imaging, and Sensing Applications. Advanced Materials, 2018, 30, e1707634.	11.1	504
72	$\mbox{\sc i}\mbox{\sc BCL3}\mbox{\sc /i}\mbox{\sc expression}$ promotes resistance to alkylating chemotherapy in gliomas. Science Translational Medicine, 2018, 10, .	5.8	52

#	Article	lF	CITATIONS
73	Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis. PLoS ONE, 2018, 13, e0195149.	1.1	99
74	Non-canonical NF-κB Antagonizes STING Sensor-Mediated DNA Sensing in Radiotherapy. Immunity, 2018, 49, 490-503.e4.	6.6	155
75	Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy. Nature Communications, 2018, 9, 2351.	5.8	253
76	Type 3 innate lymphoid cell-derived lymphotoxin prevents microbiota-dependent inflammation. Cellular and Molecular Immunology, 2018, 15, 697-709.	4.8	11
77	Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1–Resistant Tumors Leading to Tumor Eradication. Cancer Immunology Research, 2017, 5, 127-136.	1.6	17
78	Radiotherapy and immunotherapy: a beneficial liaison?. Nature Reviews Clinical Oncology, 2017, 14, 365-379.	12.5	760
79	CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response. Cell Reports, 2017, 18, 2373-2386.	2.9	81
80	Differences in Survival With Surgery and Postoperative Radiotherapy Compared With Definitive Chemoradiotherapy for Oral Cavity Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 691.	1.2	54
81	Tumour ischaemia by interferon-γ resembles physiological blood vessel regression. Nature, 2017, 545, 98-102.	13.7	199
82	InÂVivo Delivery and Therapeutic Effects of a MicroRNA on Colorectal Liver Metastases. Molecular Therapy, 2017, 25, 1588-1595.	3.7	42
83	Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer. Clinical Cancer Research, 2017, 23, 4493-4500.	3.2	15
84	Survival outcomes for postoperative chemoradiation in intermediateâ€risk oral tongue cancers. Head and Neck, 2017, 39, 2537-2548.	0.9	8
85	Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein α Signaling. Immunity, 2017, 47, 363-373.e5.	6.6	209
86	Host STING-dependent MDSC mobilization drives extrinsic radiation resistance. Nature Communications, 2017, 8, 1736.	5.8	304
87	TP53 Mutational Status and ROS Effect the Expression of the Survivin-Associated Radio-Adaptive Response. Radiation Research, 2017, 188, 659-670.	0.7	17
88	Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma. Oncotarget, 2017, 8, 18726-18734.	0.8	6
89	Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs. Oncotarget, 2016, 7, 26496-26515.	0.8	141
90	Clinical and molecular markers of longâ€ŧerm survival after oligometastasisâ€directed stereotactic body radiotherapy (SBRT). Cancer, 2016, 122, 2242-2250.	2.0	109

#	Article	lF	Citations
91	Photodynamic Therapy Mediated by Nontoxic Core–Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer. Journal of the American Chemical Society, 2016, 138, 16686-16695.	6.6	384
92	Stereotactic body radiotherapy for oligometastatic breast cancer: a new standard of care, or a medical reversal in waiting? Expert Review of Anticancer Therapy, 2016, 16, 625-632.	1.1	6
93	Chlorin-Based Nanoscale Metal–Organic Framework Systemically Rejects Colorectal Cancers via Synergistic Photodynamic Therapy and Checkpoint Blockade Immunotherapy. Journal of the American Chemical Society, 2016, 138, 12502-12510.	6.6	429
94	Very low doses of ionizing radiation and redox associated modifiers affect survivin-associated changes in radiation sensitivity. Free Radical Biology and Medicine, 2016, 99, 110-119.	1.3	12
95	Nonmuscle Myosin Light Chain Kinase Activity Modulates Radiationâ€Induced Lung Injury. Pulmonary Circulation, 2016, 6, 234-239.	0.8	9
96	The intersection of radiotherapy and immunotherapy: Mechanisms and clinical implications. Science Immunology, 2016, $1$ , .	5.6	149
97	Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy. Nature Communications, 2016, 7, 12499.	5.8	625
98	Advanced Animal Model of Colorectal Metastasis in Liver: Imaging Techniques and Properties of Metastatic Clones. Journal of Visualized Experiments, 2016, , .	0.2	5
99	Tumor-associated fibroblasts predominantly come from local and not circulating precursors.  Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 7551-7556.	3.3	139
100	Response. Journal of the National Cancer Institute, 2016, 108, djv413.	3.0	0
101	Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation. Clinical Cancer Research, 2016, 22, 2734-2743.	3.2	68
102	Linking Cancer Metabolism to DNA Repair and Accelerated Senescence. Molecular Cancer Research, 2016, 14, 173-184.	1.5	46
103	From DNA Damage to Nucleic Acid Sensing: A Strategy to Enhance Radiation Therapy. Clinical Cancer Research, 2016, 22, 20-25.	3.2	67
104	Repurposing cephalosporin antibiotics as pro-senescent radiosensitizers. Oncotarget, 2016, 7, 33919-33933.	0.8	18
105	Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance. Oncotarget, 2016, 7, 43039-43051.	0.8	62
106	A Phase 1 Study of Total Marrow Irradiation Combined with High-Dose Melphalan for Patients with Relapsed/ Refractory Multiple Myeloma. Blood, 2016, 128, 4646-4646.	0.6	0
107	Imaging of tumor clones with differential liver colonization. Scientific Reports, 2015, 5, 10946.	1.6	8
108	Evidence for the Use of Multiple Mechanisms by Herpes Simplex Virus-1 R7020 to Inhibit Intimal Hyperplasia. PLoS ONE, 2015, 10, e0130264.	1.1	1

#	Article	IF	CITATIONS
109	RAD54 family translocases counter genotoxic effects of RAD51 in human tumor cells. Nucleic Acids Research, 2015, 43, 3180-3196.	6.5	72
110	Role of GADD45a in murine models of radiation- and bleomycin-induced lung injury. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 309, L1420-L1429.	1.3	14
111	Increasing Radiation Therapy Dose Is Associated With Improved Survival in Patients Undergoing Stereotactic Body Radiation Therapy for Stage IÂNon–Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 91, 344-350.	0.4	91
112	Nanomedicine for Combination Therapy of Cancer. EBioMedicine, 2015, 2, 366-367.	2.7	19
113	Radiotherapy and immune checkpoint blockade: potential interactions and future directions. Trends in Molecular Medicine, 2015, 21, 463-465.	3.5	28
114	Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide. Cancer Research, 2015, 75, 2039-2048.	0.4	15
115	Prevalence and Predictors of Inappropriate Delivery of Palliative Thoracic Radiotherapy for Metastatic Lung Cancer. Journal of the National Cancer Institute, 2015, 107, djv278.	3.0	18
116	Protection from Radiation-Induced Pulmonary Fibrosis by Peripheral Targeting of Cannabinoid Receptor-1. American Journal of Respiratory Cell and Molecular Biology, 2015, 53, 555-562.	1.4	28
117	Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes. Clinical Cancer Research, 2015, 21, 870-881.	3.2	303
118	The Immunology of Ablative Radiation. Seminars in Radiation Oncology, 2015, 25, 40-45.	1.0	36
119	Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas. Clinical Cancer Research, 2015, 21, 632-641.	3.2	525
120	14q32-encoded microRNAs mediate an oligometastatic phenotype. Oncotarget, 2015, 6, 3540-3552.	0.8	103
121	A Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses. Molecular Therapy, 2014, 22, 1048-1055.	3.7	233
122	STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity, 2014, 41, 843-852.	6.6	1,468
123	The oligometastatic stateâ€"separating truth from wishful thinking. Nature Reviews Clinical Oncology, 2014, 11, 549-557.	12.5	245
124	Race and competing mortality in advanced head and neck cancer. Oral Oncology, 2014, 50, 40-44.	0.8	27
125	Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 149-157.	1.7	83
126	RIG-l–like receptor LGP2 protects tumor cells from ionizing radiation. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E484-91.	3.3	70

#	Article	IF	Citations
127	Comparison of carboplatin–paclitaxel to docetaxel–cisplatin-5–flurouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced head and neck cancer. Oral Oncology, 2014, 50, 52-58.	0.8	18
128	Combination of Linear Accelerator–Based Intensity-Modulated Total Marrow Irradiation and Myeloablative Fludarabine/Busulfan: A Phase I Study. Biology of Blood and Marrow Transplantation, 2014, 20, 2034-2041.	2.0	40
129	Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer. Oral Oncology, 2014, 50, 825-831.	0.8	7
130	Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs. Clinical and Experimental Metastasis, 2014, 31, 735-748.	1.7	71
131	Targeting the Tumor Microenvironment with Interferon- $\hat{l}^2$ Bridges Innate and Adaptive Immune Responses. Cancer Cell, 2014, 25, 37-48.	7.7	236
132	The Effect of Radiotherapy Dose on Survival in Stage III Non–Small-Cell Lung Cancer Patients Undergoing Definitive Chemoradiotherapy. Clinical Lung Cancer, 2014, 15, 365-371.	1.1	9
133	Effect of Postradiotherapy Neck Dissection on Nonregional Disease Sites. JAMA Otolaryngology - Head and Neck Surgery, 2014, 140, 12.	1.2	2
134	Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice. Journal of Clinical Investigation, 2014, 124, 687-695.	3.9	1,627
135	Comparison of 3D Confromal Radiotherapy and Intensity Modulated Radiotherapy with or without Simultaneous Integrated Boost during Concurrent Chemoradiation for Locally Advanced Head and Neck Cancers. PLoS ONE, 2014, 9, e94456.	1.1	44
136	DNA Repair Biomarkers XPF and Phospho-MAPKAP Kinase 2 Correlate with Clinical Outcome in Advanced Head and Neck Cancer. PLoS ONE, 2014, 9, e102112.	1.1	14
137	Loss of Nfkb1 leads to early onset aging. Aging, 2014, 6, 931-942.	1.4	78
138	Correlation of homologous recombination deficiency in head and neck cancer with sensitivity to PARP inhibition Journal of Clinical Oncology, 2014, 32, 6094-6094.	0.8	0
139	LINAC-based intensity modulated total marrow irradiation (TMI) in addition to myeloablative fludarabine/IV busulfan conditioning prior to allogeneic stem cell transplant for high-risk hematologic malignancies: A phase I study Journal of Clinical Oncology, 2014, 32, 7045-7045.	0.8	O
140	Radiation as an Immune Modulator. Seminars in Radiation Oncology, 2013, 23, 273-280.	1.0	140
141	New Paradigms and Future Challenges in Radiation Oncology: An Update of Biological Targets and Technology. Science Translational Medicine, 2013, 5, 173sr2.	5.8	197
142	Stereotactic Radiotherapy for Pulmonary Metastases. Seminars in Thoracic and Cardiovascular Surgery, 2013, 25, 292-299.	0.4	5
143	Radiation-Induced Equilibrium Is a Balance between Tumor Cell Proliferation and T Cell–Mediated Killing. Journal of Immunology, 2013, 190, 5874-5881.	0.4	140
144	DNA damage-induced cytotoxicity is mediated by the cooperative interaction of phospho-NF-κB p50 and a single nucleotide in the κB-site. Nucleic Acids Research, 2013, 41, 764-774.	6.5	153

#	Article	IF	CITATIONS
145	Myeloablative Fludarabine/ IV Busulfan Combined With Linac Based Intentsity Modulated Total Marrow Irradiation (IM-TMI) In Allogeneic Stem Cell Transplant For High Risk Hematologic Malignancies: A Phase I Study. Blood, 2013, 122, 3285-3285.	0.6	0
146	Oligo- and Polymetastatic Progression in Lung Metastasis(es) Patients Is Associated with Specific MicroRNAs. PLoS ONE, 2012, 7, e50141.	1.1	181
147	Stereotactic body radiotherapy for multisite extracranial oligometastases. Cancer, 2012, 118, 2962-2970.	2.0	295
148	Incidence and implications of oligometastatic breast cancer Journal of Clinical Oncology, 2012, 30, e11512-e11512.	0.8	18
149	p50 (NF-κB1) Is an Effector Protein in the Cytotoxic Response to DNA Methylation Damage. Molecular Cell, 2011, 44, 785-796.	4.5	49
150	MicroRNA Expression Characterizes Oligometastasis(es). PLoS ONE, 2011, 6, e28650.	1.1	242
151	The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon–Dependent Innate and Adaptive Immunity. Cancer Research, 2011, 71, 2488-2496.	0.4	692
152	Anti-Leukemic Activity Is Increased with Low Dose Busulfan and Irradiation: A Preclinical Model. Blood, 2011, 118, 4696-4696.	0.6	0
153	Radioresistance of Stat1 over-expressing tumour cells is associated with suppressed apoptotic response to cytotoxic agents and increased IL6-IL8 signalling. International Journal of Radiation Biology, 2009, 85, 421-431.	1.0	46
154	Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood, 2009, 114, 589-595.	0.6	1,146
155	An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 18490-18495.	3.3	484
156	MUCing around with tumor suppression. Cancer Biology and Therapy, 2008, 7, 1968-1969.	1.5	O
157	More on Cetuximab in Head and Neck Cancer. New England Journal of Medicine, 2007, 357, 2201-2203.	13.9	12
158	Inhibition of Nuclear Factor-κB Activity by Temozolomide Involves <i>O</i> 6-Methylguanine–Induced Inhibition of p65 DNA Binding. Cancer Research, 2007, 67, 6889-6898.	0.4	36
159	How does antiangiogenic therapy affect brain tumor response to radiation?. Nature Clinical Practice Oncology, 2005, 2, 232-233.	4.3	8
160	Bugging the intestinal response to radiation. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13363-13364.	3.3	3
161	Transcriptional Targeting of Adenovirally Delivered Tumor Necrosis Factor α by Temozolomide in Experimental Glioblastoma. Cancer Research, 2004, 64, 6381-6384.	0.4	45
162	STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1714-1719.	3.3	273

#	Article	IF	Citations
163	Radiation-induced tumour necrosis factor-α expression: clinical application of transcriptional and physical targeting of gene therapy. Lancet Oncology, The, 2002, 3, 665-671.	5.1	80
164	Changing face and different countenances of prostate cancer:Racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. International Journal of Cancer, 2001, 96, 363-371.	2.3	57
165	Genetically engineered HSV in the treatment of glioma: a review. , 2000, 10, 17-30.		74
166	Hsp27 functions as a negative regulator of cytochrome c-dependent activation of procaspase-3. Oncogene, 2000, 19, 1975-1981.	2.6	284
167	E2F Proteins Are Posttranslationally Modified Concomitantly with a Reduction in Nuclear Binding Activity in Cells Infected with Herpes Simplex Virus 1. Journal of Virology, 2000, 74, 7842-7850.	1.5	27
168	p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature, 1999, 399, 814-817.	13.7	551
169	Oxidative Cell Membrane Alteration: Evidence for Surfactant-Mediated Sealinga. Annals of the New York Academy of Sciences, 1999, 888, 274-284.	1.8	22
170	Function for p300 and not CBP in the apoptotic response to DNA damage. Oncogene, 1999, 18, 5714-5717.	2.6	54
171	Activation of protein kinase C $\hat{\Gamma}$ by the c-Abl tyrosine kinase in response to ionizing radiation. Oncogene, 1998, 16, 1643-1648.	2.6	143
172	Functional role for the c-Abl tyrosine kinase in meiosis l. Oncogene, 1998, 16, 1773-1777.	2.6	45
173	Determination of cell fate by c-Abl activation in the response to DNA damage. Oncogene, 1998, 17, 3309-3318.	2.6	160
174	Functional interaction between DNA-PK and c-Abl in response to DNA damage. Nature, 1997, 386, 732-735.	13.7	259
175	Acute toxicity in radiotherapy of prostate cancer:Results of a randomized study with and without beam's-eye view three-dimensional conformal therapy. Radiation Oncology Investigations, 1996, 4, 231-238.	1.3	3
176	Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. Nature, 1996, 382, 272-274.	13.7	232
177	Tumor size does not limit radiation-inducible gene therapy in a human xenograft model. Radiation Oncology Investigations, 1995, 3, 238-242.	1.3	3
178	Activation of the c-Abl tyrosine kinase in the stress response to DMA-damaging agents. Nature, 1995, 376, 785-788.	13.7	496
179	Stress response genes induced in mammalian cells by ionizing radiation. Radiation Oncology Investigations, 1993, 1, 81-93.	1.3	18
180	Concomitant Chemoradiotherapy With Cisplatin, 5-Fluorouracil and Hydroxyurea in Poor-Prognosis Head and Neck Cancer. Laryngoscope, 1992, 102, 630-636.	1.1	25

#	Article	IF	Citations
181	Differential retention of tumor- and differentiation-suppressor functions in cells derived from a human squamous cell carcinoma. Molecular Carcinogenesis, 1992, 5, 278-285.	1.3	1
182	Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes. Journal of Surgical Oncology, 1991, 46, 31-36.	0.8	89
183	Radiation or surgery for chemodectoma of the temporal bone: A review of local control and complications. Head and Neck, 1990, 12, 303-307.	0.9	101
184	Monosomy 12p in a radiation-induced germ cell tumor. Genes Chromosomes and Cancer, 1990, 2, 186-190.	1.5	9
185	A randomized study comparing two regimens of neoadjuvant and adjuvant chemotherapy in multimodal therapy for locally advanced head and neck cancer. Cancer, 1990, 66, 206-213.	2.0	33
186	Radiobiological Characterization of 53 Human Tumor Cell Lines. International Journal of Radiation Biology, 1989, 56, 553-560.	1.0	78
187	Radioresistant tumor cell lines derived from head and neck radiation failures. Head and Neck, 1989, 11, 343-348.	0.9	6
188	A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer. Cancer, 1989, 63, 30-36.	2.0	42
189	Concomitant Hydroxyurea, 5â€Fluorouracil, and Radiation Therapy for Recurrent Head and Neck Cancer: Early Results. Otolaryngology - Head and Neck Surgery, 1988, 98, 295-298.	1.1	11
190	Antipain-mediated suppression of sister chromatid exchanges induced by an inhibitor of poly (ADP-ribose) polymerase. Environmental Mutagenesis, 1985, 7, 703-709.	1.4	9